A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers

NCT01717157 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Treatment A: DUROGESIC (8.4 mg fentanyl)
DRUG: Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)
DRUG: Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)
DRUG: Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
DRUG: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

Sponsor

Janssen Research & Development, LLC